Please assess the completion status of the following clinical trial:

Trial Title: An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant was a man or woman ≥18 years of age.~* The participant had read, signed, and dated an informed consent form (ICF) prior to any study procedures being performed.~* At the time of enrolment, the participant had been scheduled via written documentation to undergo an ICA for the assessment of CAD.~* The participant had undergone a clinically indicated SPECT OR the participant was willing to undergo SPECT MPI for the purposes of the clinical study.~* The participant was male or was a nonpregnant, nonlactating female who was either surgically sterile or was post-menopausal.~* The participant was able and willing to comply with all study procedures as described in the protocol.~Exclusion Criteria:~* Participants who were pregnant, may possibly be pregnant, or wish (including their partners) to became pregnant during the study period, or were lactating.~* Participants who were unable to undergo all of the imaging procedures.~* Participants who had an established diagnosis of CAD as confirmed by any of the following:~  1. Previous myocardial infarction (MI);~ 2. Previous cardiac catheter angiography showing ≥50% stenosis;~ 3. Previous coronary revascularisation, such as percutaneous coronary intervention (PCI), thrombolysis or coronary artery bypass graft (CABG) placement.~* Participants incapable of undergoing either exercise or pharmacological cardiac stress testing.~* Participants who had a current illness or pathology that, in the opinion of the investigator, would pose a significant safety risk for the participant during cardiac stress testing.~* Documented history of heart failure and/or cardiomyopathy and/or prior LV ejection fraction (LVEF) \<50%).~* Participants scheduled for or planning to undergo any cardiac interventional procedures between enrolment and ICA.~* Participants undergoing evaluation for heart transplantation or with history of heart transplantation.~* Participants enrolled in another clinical study within the 30 days prior to being enrolled in this study or scheduled to participate in another clinical study during the 7-day follow-up period of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Flurpiridaz PET MPI (following off-study SPECT MPI)

Based on this trial design, predict the completion outcome and termination type (if applicable).